First, while gene ablation and pharmacological inhibition of S100B yielded significant effects on glial cell behavior and MS-related processes, the extent of S100B knockdown was not quantitatively verified, leaving uncertainty about residual protein levels and their potential functional impact. Here, S100B is linked to myeloid sarcoma.